Brooks Laboratories Vergangene Ertragsentwicklung
Vergangenheit Kriterienprüfungen 0/6
Brooks Laboratories has been growing earnings at an average annual rate of 0.3%, while the Life Sciences industry saw earnings growing at 20.2% annually. Revenues have been growing at an average rate of 2.3% per year.
Wichtige Informationen
0.3%
Wachstumsrate der Gewinne
7.3%
EPS-Wachstumsrate
| Life Sciences Wachstum der Industrie | 11.2% |
| Wachstumsrate der Einnahmen | 2.3% |
| Eigenkapitalrendite | -26.7% |
| Netto-Marge | -21.5% |
| Letzte Ertragsaktualisierung | 30 Jun 2024 |
Jüngste Aktualisierungen vergangener Leistungen
Recent updates
Would Brooks Laboratories (NSE:BROOKS) Be Better Off With Less Debt?
Sep 28
Does Brooks Laboratories (NSE:BROOKS) Have A Healthy Balance Sheet?
Jun 10Estimating The Intrinsic Value Of Brooks Laboratories Limited (NSE:BROOKS)
Feb 22Is Brooks Laboratories (NSE:BROOKS) Using Too Much Debt?
Dec 08Is Brooks Laboratories (NSE:BROOKS) A Risky Investment?
Jul 07Here's Why Brooks Laboratories (NSE:BROOKS) Can Afford Some Debt
Jan 05Brooks Laboratories (NSE:BROOKS) Is Making Moderate Use Of Debt
Sep 22
Aufschlüsselung der Einnahmen und Ausgaben
Wie Brooks Laboratories Geld verdient und ausgibt. Basierend auf den neuesten gemeldeten Einnahmen der letzten zwölf Monate.
Gewinn- und Umsatzhistorie
| Datum | Einnahmen | Umsatz | Allgemeine und Verwaltungskosten | F&E-Ausgaben |
|---|---|---|---|---|
| 30 Jun 24 | 817 | -175 | 108 | 0 |
| 31 Mar 24 | 795 | -196 | 108 | 0 |
| 31 Dec 23 | 745 | -143 | 109 | 0 |
| 30 Sep 23 | 680 | -154 | 122 | 0 |
| 30 Jun 23 | 618 | -185 | 144 | 0 |
| 31 Mar 23 | 632 | -209 | 177 | 0 |
| 31 Dec 22 | 790 | -202 | 209 | 0 |
| 30 Sep 22 | 827 | -218 | 217 | 0 |
| 30 Jun 22 | 865 | -219 | 207 | 0 |
| 31 Mar 22 | 912 | -113 | 195 | 0 |
| 31 Dec 21 | 778 | -299 | 180 | 0 |
| 30 Sep 21 | 788 | -258 | 166 | 0 |
| 30 Jun 21 | 872 | -176 | 154 | 0 |
| 31 Mar 21 | 772 | -194 | 146 | 0 |
| 31 Dec 20 | 815 | -180 | 145 | 0 |
| 30 Sep 20 | 808 | -183 | 142 | 0 |
| 30 Jun 20 | 653 | -235 | 139 | 0 |
| 31 Mar 20 | 697 | -244 | 140 | 0 |
| 31 Dec 19 | 660 | -154 | 143 | 0 |
| 30 Sep 19 | 612 | -149 | 143 | 0 |
| 30 Jun 19 | 612 | -148 | 126 | 0 |
| 31 Mar 19 | 550 | -148 | 125 | 0 |
| 31 Dec 18 | 544 | -101 | 126 | 0 |
| 30 Sep 18 | 602 | -106 | 127 | 0 |
| 30 Jun 18 | 592 | -116 | 127 | 0 |
| 31 Mar 18 | 557 | -138 | 126 | 0 |
| 31 Dec 17 | 555 | -124 | 114 | 0 |
| 30 Sep 17 | 487 | -93 | 103 | 0 |
| 30 Jun 17 | 493 | -56 | 88 | 0 |
| 31 Mar 17 | 575 | 17 | 88 | 0 |
| 31 Dec 16 | 639 | 75 | 83 | 0 |
| 30 Sep 16 | 707 | 98 | 82 | 0 |
| 30 Jun 16 | 774 | 108 | 77 | 0 |
| 31 Mar 16 | 800 | 106 | 75 | 0 |
| 31 Dec 15 | 828 | 84 | 147 | 0 |
| 30 Sep 15 | 856 | 73 | 141 | 0 |
| 30 Jun 15 | 867 | 94 | 49 | 0 |
| 31 Mar 15 | 852 | 95 | 58 | 0 |
| 31 Dec 14 | 805 | 91 | 139 | 0 |
| 30 Sep 14 | 760 | 88 | 134 | 0 |
| 30 Jun 14 | 796 | 69 | 126 | 0 |
| 31 Mar 14 | 853 | 72 | 139 | 0 |
| 31 Dec 13 | 888 | 49 | 91 | 0 |
Qualität der Erträge: BROOKS is currently unprofitable.
Wachsende Gewinnspanne: BROOKS is currently unprofitable.
Analyse von freiem Cashflow und Gewinn
Analyse des Gewinnwachstums in der Vergangenheit
Ergebnisentwicklung: BROOKS is unprofitable, but has reduced losses over the past 5 years at a rate of 0.3% per year.
Beschleunigtes Wachstum: Unable to compare BROOKS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Erträge im Vergleich zur Industrie: BROOKS is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (13.3%).
Eigenkapitalrendite
Hohe Eigenkapitalrendite: BROOKS has a negative Return on Equity (-26.74%), as it is currently unprofitable.